BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mascarenhas MR. Treatment of gastrointestinal problems in cystic fibrosis. Curr Treat Options Gastro 2003;6:427-41. [DOI: 10.1007/s11938-003-0045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Vitko M, Valerio DM, Rye PD, Onsøyen E, Myrset AH, Dessen A, Drumm ML, Hodges CA. A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice. Journal of Cystic Fibrosis 2016;15:745-51. [DOI: 10.1016/j.jcf.2016.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kopřiva F, Michálková K, Zápalka M, Malý J. Potato crisps without pancreatic extracts supplements: a potential cause of the distal intestinal obstruction in cystic fibrosis. Eur J Pediatr 2007;166:969-70. [DOI: 10.1007/s00431-006-0326-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Smith VV, Schäppi MG, Bisset WM, Kiparissi F, Jaffe A, Milla PJ, Lindley KJ. Lymphocytic Leiomyositis and Myenteric Ganglionitis Are Intrinsic Features of Cystic Fibrosis: Studies in Distal Intestinal Obstruction Syndrome and Meconium Ileus. Journal of Pediatric Gastroenterology & Nutrition 2009;49:42-51. [DOI: 10.1097/mpg.0b013e318186d35a] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
4 Michel SH, Mallowe A. Nutrition Management of the Infant Identified With Cystic Fibrosis. Topics in Clinical Nutrition 2012;27:260-9. [DOI: 10.1097/tin.0b013e3182625b3c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Bradford EM, Sartor MA, Gawenis LR, Clarke LL, Shull GE. Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G886-G898. [PMID: 19164484 DOI: 10.1152/ajpgi.90520.2008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
6 Trapnell BC, Strausbaugh SD, Woo MS, Tong SY, Silber SA, Mulberg AE, Leitz G. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros 2011;10:350-6. [PMID: 21632288 DOI: 10.1016/j.jcf.2011.04.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
7 Brulet M, Seyer A, Edelman A, Brunelle A, Fritsch J, Ollero M, Laprévote O. Lipid mapping of colonic mucosa by cluster TOF-SIMS imaging and multivariate analysis in cftr knockout mice. J Lipid Res 2010;51:3034-45. [PMID: 20616379 DOI: 10.1194/jlr.M008870] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
8 Walayat S, Hussain N, Patel J, Hussain F, Patel P, Dhillon S, Aulakh B, Chittivelu S. Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma. Int Med Case Rep J 2017;10:243-6. [PMID: 28769592 DOI: 10.2147/IMCRJ.S139022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Michel SH, Mueller DH. Nutrition for pregnant women who have cystic fibrosis. J Acad Nutr Diet 2012;112:1943-8. [PMID: 23174681 DOI: 10.1016/j.jand.2012.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Bradford EM, Sartor MA, Gawenis LR, Clarke LL, Shull GE. Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G886-G898. [PMID: 19164484 DOI: 10.1152/ajpgi.90520] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Kaur S, Norkina O, Ziemer D, Samuelson LC, De Lisle RC. Acidic duodenal pH alters gene expression in the cystic fibrosis mouse pancreas. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004;287:G480-90. [DOI: 10.1152/ajpgi.00035.2004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
12 Rye PD, Tøndervik A, Sletta H, Pritchard M, Kristiansen A, Dessen A, Thomas DW. Alginate Oligomers and Their Use as Active Pharmaceutical Drugs. In: Rehm BH, Moradali MF, editors. Alginates and Their Biomedical Applications. Singapore: Springer; 2018. pp. 237-56. [DOI: 10.1007/978-981-10-6910-9_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
13 Norkina O, De Lisle RC. Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10. BMC Genet 2005;6:29. [PMID: 15921521 DOI: 10.1186/1471-2156-6-29] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]